Lifevantage (NASDAQ:LFVN) Releases Earnings Results, Misses Estimates By $0.04 EPS

Lifevantage (NASDAQ:LFVN) issued its quarterly earnings results on Wednesday. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.04), FiscalAI reports. Lifevantage had a return on equity of 29.59% and a net margin of 3.74%.The business had revenue of $43.72 million during the quarter, compared to analyst estimates of $47.77 million.

Here are the key takeaways from Lifevantage’s conference call:

• The company reported net revenue of $43.7 million, down 25.2% year‑over‑year, driven mainly by weaker sales of the MindBody GLP‑1 System and fewer active accounts, and now expects fiscal 2026 results near the lower end of prior guidance.
• Profitability pressures included a decline in gross margin to 79% (81% prior year) from higher shipping/warehouse costs and inventory obsolescence, with Q3 GAAP net income falling to $1.4 million ($0.11/share).
• Financial position remains solid with $12.5 million cash, no debt, $5.5 million of cash from operations year‑to‑date, an active share repurchase program (board authorized $60 million, ~$59 million remaining), and an 11% higher quarterly dividend of $0.05 per share.
• Management is pursuing strategic initiatives to boost growth, including an e‑commerce and back‑office upgrade via Shopify rollout later this year and a newly announced 12‑month VIP bonus incentive aimed at accelerating consultant growth and leadership development.
• Product and leadership catalysts include the U.S. patent for the Healthy Glow Essentials Stack, the October convention where a new product launch is planned, the LoveBiome/P84 additions to the portfolio, and the appointment of Terrence Moorehead as CEO joining in August.

Lifevantage Stock Up 9.3%

Shares of Lifevantage stock traded up $0.51 during trading hours on Wednesday, hitting $6.00. 814,778 shares of the company’s stock traded hands, compared to its average volume of 214,839. Lifevantage has a twelve month low of $3.90 and a twelve month high of $15.00. The company has a market cap of $76.86 million, a PE ratio of 10.00 and a beta of 0.52. The stock has a 50 day simple moving average of $4.70 and a 200-day simple moving average of $5.81.

Insider Buying and Selling

In other Lifevantage news, Director Judd Dayton acquired 18,097 shares of the stock in a transaction on Friday, February 27th. The stock was purchased at an average price of $4.63 per share, for a total transaction of $83,789.11. Following the purchase, the director directly owned 69,859 shares in the company, valued at $323,447.17. This trade represents a 34.96% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders bought a total of 38,207 shares of company stock valued at $178,585 over the last ninety days. Corporate insiders own 21.95% of the company’s stock.

Institutional Trading of Lifevantage

A number of hedge funds and other institutional investors have recently made changes to their positions in LFVN. Goldman Sachs Group Inc. boosted its stake in Lifevantage by 305.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 200,222 shares of the company’s stock valued at $1,233,000 after acquiring an additional 150,785 shares during the last quarter. Geode Capital Management LLC increased its holdings in Lifevantage by 106.1% in the second quarter. Geode Capital Management LLC now owns 245,332 shares of the company’s stock valued at $3,210,000 after buying an additional 126,274 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Lifevantage by 8.3% during the 4th quarter. Renaissance Technologies LLC now owns 922,918 shares of the company’s stock worth $5,685,000 after buying an additional 70,900 shares during the last quarter. Advyzon Investment Management LLC grew its position in shares of Lifevantage by 346.3% in the 4th quarter. Advyzon Investment Management LLC now owns 62,277 shares of the company’s stock worth $384,000 after acquiring an additional 48,322 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Lifevantage in the 4th quarter valued at approximately $289,000. Institutional investors own 35.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Weiss Ratings lowered Lifevantage from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday. Lake Street Capital reaffirmed a “buy” rating on shares of Lifevantage in a research report on Thursday, February 5th. Finally, Loop Capital set a $5.00 price objective on Lifevantage in a research note on Thursday, February 5th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Lifevantage Company Profile

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.